Peptide record

TPDB92471

LL-III/23 Antibacterial Anticancer Antifungal Toxicity modified_plain modified
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB92471
LL-III/23
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF CAFPdb
modified_plain
Yes
A 15-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from Peptipedia, AntiCP 2.0, CancerPPD 2.0, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
VNWKKLLGKLLKVVK-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
15 reviewed residue count
Amidation Activity
L Activity
Linear Activity
Free Activity
Antimicrobial and Antifungal Activity
Lasioglossin III and its analogs Activity
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 4 µM
Anticancer
4 µM

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 15 µM
Anticancer
15 µM

Target

Colon Cancer
SW
Colon

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 3 Activity

Activity

IC50
IC50 = 6 µM
Anticancer
6 µM

Target

Leukemia Cancer
CCRF-CEM
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012